- Waldenström Macroglobulinemia
- Melanoma
- Bladder Cancer
- Brain Cancer
- Breast Cancer
- Childhood Cancers
- Gastric Cancer
- Gynecologic Cancer
- Head & Neck Cancer
- Immunotherapy
- Kidney Cancer
- Leukemia
- Liver Cancer
- Lung Cancer
- Lymphoma Cancer
- Mesothelioma
- MPN
- MDS
- Myeloma
- Prostate Cancer
- Rare Cancers
- Sarcoma
- Skin Cancer
- Testicular Cancer
- Thyroid Cancer
Founding 'Faery' Shares Resources and Inspiration Behind Blue Faery Liver Cancer Association
Andrea Wilson, president and founder of Blue Faery: The Adrienne Wilson Liver Cancer Association, spoke with CURE® at the 2019 ASCO meeting about the loss of her sister and how it inspired her to found Blue Faery.
After realizing no organizations existed for patients with hepatocellular carcinoma (HCC) and their caregivers, Andrea Wilson founded Blue Faery: The Adrienne Wilson Liver Cancer Association to help prevent, treat and cure liver cancer through research, education and advocacy.
Wilson founded Blue Faery about a year and a half after her sister passed away in 2001 — just 147 days with the disease. “I knew the rate of liver cancer was going to rise in this country. I didn’t want anyone else to go through what we did.”
At the 2019 American Society of Clinical Oncology Annual Meeting, Wilson spoke about the loss of her sister and how it inspired her to found Blue Faery, while also sharing, information about the resources available, such as the online forum for patients and caregivers.
Tecentriq Plus Perjeta, Chemo Does Not Improve pCR in HER2+ Breast Cancer
December 8th 2023A recent phase 3 APTneo Michelangelo trial added Tecentriq to neoadjuvant Herceptin plus Perjeta and chemotherapy which did not lead to a statistically significant improvement in pathologic complete response in patients with HER2-positive operable breast cancer.
Read More
Creating a Charity 8 Days After a Rare Cancer Diagnosis: Dying Defiantly Founder Shares His Story
December 8th 2022After Marshall Morris was diagnosed with a rare cancer and given only six months to live, he created a charity that empowers people with terminal illness and provides them with counseling and support.
Listen
Dato-DXd Extends PFS in HR+/HER2- Inoperable or Metastatic Breast Cancer
December 7th 2023Dato-DXd (datopotamab deruxtecan) as a form of treatment compared to chemotherapy resulted in improved progression-free survival for patients with previously treated hormone receptor-positive/HER2-negative inoperable or metastatic breast cancer.
Read More
Tukysa Plus Kadcyla Improves PFS in Previously Treated HER2+ Metastatic Breast Cancer
December 7th 2023The introduction of Tukysa to Kadcyla emtansine significantly improved progression-free survival versus placebo plus Kadcyla in patients with previously treated HER2-positive metastatic breast cancer.
Read More
